Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
This article was originally published in The Tan Sheet
Executive Summary
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
You may also be interested in...
Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.
Allegra Brand Revision Will Sell Romance, Emotion
The OTC Allegra package branding when launched in March 2011 was limited by FDA until after the product lost market exclusivity, consultant Terri Goldstein says. Loss of market exclusivity opened the door to make Allegra branding “how we wished the package could have looked,” she says.
Zyrtec Model Shows Managed Care’s “Softer” Side For Switching Patients
Sales of Johnson & Johnson's allergy drug Zyrtec show managed care organizations learned from previous switches and used a "softer" approach to steer clients away from Rx drugs to an OTC product, according to market analysts